FMI’s projections indicate that the worldwide allergy immunotherapy market is on a trajectory to attain a valuation of approximately US$ 1.74 billion in 2023. Demonstrating robust growth at an impressive compound annual growth rate (CAGR) of 8.9% from 2023 to 2033, the market is expected to surpass the US$ 4.07 billion mark by 2033.
While the immunotherapy treatment market has garnered substantial attention for its innovative approach to combatting cancer, it’s noteworthy that the expanding allergy immunotherapy market leverages similar immunotherapy principles in the treatment of allergies.
Request a Sample Report Today to get Premium Insights:
https://www.futuremarketinsights.com/reports/sample/rep-gb-9043
The predicted revenue growth could be related to the burden of allergy conditions, which are becoming more prevalent globally. The responsibility that complex allergies with increased morbidity place on the healthcare system motivates research and development in this area for the introduction of innovative medicines.
The primary factors propelling the global market are:
- The expansion of industrialization and population.
- Improvements in healthcare and medicine.
- The launch of novel immunotherapeutic medications.
Current regulatory approvals, such as those for oral dissolvable tablets, are further enhanced to gain a larger global allergy immunotherapy market share.
Compared to other treatments already on the market, sublingual allergy immunotherapy has been clinically shown to be more effective and have fewer adverse effects. Another factor influencing the allergy immunotherapy market growth is the demographic shift in the population and the macroeconomic environment.
The prevalence of asthma and allergy respiratory illnesses has increased due to rising air pollution levels inside and outside. According to the Asthma and Allergy Association of America (AAFA), rising pollen levels cause more than 25 million allergies.
Europe and North America are the two leading markets for allergy immunotherapy, and they are likely to continue holding a sizable market share during the forecast period. Given the increased awareness, healthcare reimbursement regulations, and growth in the population who suffer from allergies, Europe is estimated to hold a significant portion of the global allergy immunotherapy market.
Methodology Details Just a Click Away!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-9043
“Allergy immunotherapy represents a transformative approach to allergy treatment. This therapeutic method offers long-term relief by desensitizing the immune system to allergens, fundamentally changing how we manage allergies and providing hope for sufferers worldwide.”—by Lead Analyst at Future Market Insights.
KEY TAKEAWAYS:
- The market in the United Kingdom is anticipated to rise, exhibiting a CAGR of 9.1% through 2033.
- The United States is expected to develop at a 9.1% CAGR during the forecast period.
- With a CAGR of 9.3% over the forecast period, Canada is predicted to grow rapidly in the market.
- The market in China is expected to increase, registering a CAGR of 8.8% over the forecast period.
- Germany is estimated to grow decently, registering a CAGR of 9.7% until 2033.
COMPETITIVE LANDSCAPE:
Top players operating in the allergy immunotherapy market are ALK Abello, Stallergenes Greer, Allergy Therapeutics, Aimmune Therapeutics, Anergis, Arrayit Corporation, Biomay AG, HAL Allergy Group, DBV Technologies, and others.
These key players in the market are developing innovative products, such as sublingual and subcutaneous immunotherapy, to cater to the growing demand for effective allergy treatments. They also invest in research and development to improve existing therapies’ efficacy and safety and expand their market reach through strategic partnerships and collaborations.
RECENT DEVELOPMENTS:
- In September 2021, ALK confirmed that by expanding the number of patients by at least 100,000 yearly, it intends to make allergy testing, immunotherapy treatments, and adrenaline products accessible by 2030.
- In June 2021, with the complete restoration of SCIT manufacturing in Antony, Stallergenes Greer declared that Alustal®, its subcutaneous allergen immunotherapy (SCIT) remedy, is now accessible in Italy and Spain.
Level Up Your Market Understanding – Buy Now!
https://www.futuremarketinsights.com/checkout/9043
Allergy Immunotherapy Market Segmentation:
Product:
- SLIT Tablets
-
- Odactra
- Grastek
- Ragwitek
- Oralair
- Actair
- Others
- Oral
- Palforzia
- Others
- Injections
- Others
Immunotherapy:
- Sublingual Immunotherapy
- Subcutaneous Immunotherapy
-
- Specific Immunotherapy
- Others
Indication:
- Allergic Rhinitis
- Allergic Asthma
- Food Allergy
- Atopic Dermatitis
- Others
Allergen:
- Pollens
-
- Grass Pollens
- Weed Pollens
- Tree Pollens
- House Dust Mites
- Mold
- Animal Dander
- Bee Venom
- Cockroaches/Insects
- Others
Distribution Channel:
- Institutional Sales
-
- Government Hospitals
- Semi-Government Hospitals
- Private Hospitals
- Retail Sales
- Retail Pharmacy
- Drug Stores
- Online Pharmacy
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
